

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 August 2024 (29.08.2024)



(10) International Publication Number
WO 2024/176147 A1

(51) International Patent Classification:

A61K 51/08 (2006.01) A61K 38/34 (2006.01)
A61K 31/519 (2006.01) A61K 45/06 (2006.01)
A61K 31/565 (2006.01) A61P 35/00 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2024/051682

(22) International Filing Date:

21 February 2024 (21.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/486,496 23 February 2023 (23.02.2023) US
63/625,371 26 January 2024 (26.01.2024) US

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35,
4056 Basel (CH).

(72) Inventors: **AIMONE, Paola Daniela**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **BLUMENSTEIN, Lars**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **CACCIATORE, Silvia**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **CHERFI, Azzeddine**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **PATHAK, Dhrubajyoti**; Novartis Pharma AG, Lichtstrasse 35, 4056 Basel (CH). **PERRAUD, Kevin**; Advanced Accelerator Applications International SA, Rue de la Tour de L'Ile 4, 1204 Geneva (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: METHODS FOR TREATING BREAST CANCER

(57) Abstract: The present disclosure is directed to methods of treating breast cancer in a subject in need thereof comprising administering to said subject a therapeutically effective amount of a radiopharmaceutical compound with GRPR antagonist moiety, e.g. [¹⁷⁷Lu]Lu-NeoB, in combination with a CDK4/6 inhibitor, e.g. ribociclib, and with a therapeutically effective amount of an endocrine treatment, e.g. fulvestrant.

WO 2024/176147 A1